Thông tin thuốc gốc
Chỉ định và Liều dùng
Resistant schizophrenia, Severe schizophrenia
Adult: Initially, 25 mg. Repeat after 30-60 min if necessary; up to 200 mg daily has been given.

Resistant schizophrenia, Severe schizophrenia
Adult: Initially, 25-50 mg tid. May adjust dose to 100-400 mg according to response.
Hướng dẫn pha thuốc
Dilute oral concentrate just prior to admin with distilled water, acidified tap water, orange or grape juice. Do not prepare and store bulk dilutions.
Tương kỵ
Do not mix oral solutions of mesoridazine and lithium.
Chống chỉ định
Severe CNS depression and coma; prolonged QT interval (>450 msec), including congenital prolongation; history of arrhythmias. Lactation.
Thận trọng
Admin to patients only if baseline QTc <450 msec. Discontinue if QTc interval >500 msec. Monitor potassium levels. CNS depression; Parkinson's disease; haemodynamic instability; bone marrow suppression; predisposition to seizures; subcortical brain damage; severe cardiac, hepatic, renal or respiratory disease; patients at risk of pneumonia (e.g. Alzheimer's disease); breast cancer or other prolactin-dependent tumours. May alter temperature regulation or mask toxicity of other drugs. Patients at risk of orthostatic hypotension; cerebrovascular disease, CVD. Decreased GI motility, urinary retention, benign prostatic hyperplasia, xerostomia or visual problems. Narrow-angle glaucoma and myasthenia gravis. Pregnancy.
Tác dụng không mong muốn
Hypotension, orthostatic hypotension, tachycardia, cardiac arrhythmias, sinus tachycardia; sedation, drowsiness, restlessness, anxiety, extrapyramidal symptoms, pseudoparkinsonian signs, tardive dyskinesia, neuroleptic malignant syndrome, seizures, altered central temperature regulation, akathisia, dystonias, dizziness, hyperthermia; hypersensitivity reactions; amenorrhoea, galactorrhoea, gynaecomastia, syndrome of inappropriate antidiuretic hormone; GI upset, xerostomia, constipation, wt gain; urinary retention, impotence; agranulocytosis, leukopenia, thrombocytopenia, haemolysis, eosinophilia; cholestatic jaundice; trismus; retinal pigmentation, nystagmus, blurred vision; nasal congestion; decreased diaphoresis, SLE.
Quá liều
Symptoms: Involuntary muscle movements, haematological disturbances (e.g. agranulocytosis, leukopenia), arrhythmias, coma, deep sleep, ejaculatory disturbances, enuresis, extrapyramidal reaction, galactorrhoea, gynaecomastia, hypotension, impotence, neuroleptic malignant syndrome, nystagmus, Parkinson's-like symptoms, photophobia, priapism, QRS prolongation, urine discolouration, vision colour changes. Management: Activated charcoal or gastric lavage within 1 hr. Supportive therapy. Multiple dosing of activated charcoal may be useful; not dialysable.
Tương tác
Increased risk of extrapyramidal symptoms (EPS) with central acetylcholinesterase inhibitors. Reduced absorption with aluminium salts. Reduced efficacy of amphetamines; increased risk of psychotic symptoms with amphetamines. Reduced efficacy or excess anticholinergic effects with anticholinergics. Additive hypotensive effects with antihypertensives, trazodone. May inhibit effects of bromocriptine on serum prolactin levels. Additive sedative effects with CNS depressants. May diminish effects of epinephrine. May inhibit the antiparkinsonian effect of levodopa. May increase risk of EPS with metoclopramide. Increased risk of neurotoxicity with lithium (rare). Increased serum levels with sulfadoxime-pyrimethamine. Increased toxicity or altered response with TCAs. May increase serum levels of valproic acid.
Potentially Fatal: Increased risk of malignant arrhythmias with other QTc-prolonging agents.
Ảnh hưởng đến kết quả xét nghiệm
May cause false-positive results when testing for TCAs through the EMIT system.
Tác dụng
Description: Mesoridazine is a phenothiazine antipsychotic. It has a piperidine side-chain and is a metabolite of thioridazine. It acts by blocking postsynaptic CNS dopamine receptors.
Onset: 30 min to 1 hr.
Duration: 4-6 hr.
Absorption: Tablet: Erratic; Liquid: More dependable. Peak serum concentrations in 2-4 hr.
Distribution: Widely distributed into body including breast milk. Protein-binding: 91-99%.
Metabolism: Hepatic.
Excretion: Mainly via urine; 24-48 hr (elimination half-life).
Bảo quản
Store at 25°C (77°F).
Tablet: Store at 25°C (77°F). Oral solution: Store below 25°C (77°F); protect from light.
Phân loại MIMS
Thuốc chống loạn thần
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mesoridazine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in